Evidence map›Paper›PMID 37605283›Full record

SynthesisSystematic reviews2023

Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study.

Amirhossein Naghipour, Ehsan Amini-Salehi, Mahdi Orang Gorabzarmakhi, Milad Shahdkar, Bahman Fouladi, Iraj Alipourfard, Zahra Momayez Sanat

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Systematic reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 6 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 6 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Amirhossein NaghipourDepartment of Pharmaceutics, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.ORCID http://orcid.org/0000-0003-0410-6745
Ehsan Amini-SalehiGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Mahdi Orang GorabzarmakhiGuilan University of Medical Sciences, Rasht, Iran.
Milad ShahdkarGuilan University of Medical Sciences, Rasht, Iran.
Bahman FouladiPediatric Gastroenterology and Hepatoloy Research center, Zabol University of Medical Sciences, Zabol, Iran.
Iraj AlipourfardInstitute of Physical Chemistry, Polish Academy of Sciences, Marsaw, Poland.
Zahra Momayez SanatDigestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran. msanat.tums@gmail.com.
Guilan University of Medical Sciences · IRInstitute of Physical Chemistry · PLKerman University of Medical Sciences · IRTehran University of Medical Sciences · IRZabol University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-alcoholic fatty liver disease (NAFLD), the most common liver disease, is closely associated with metabolic conditions such as obesity and diabetes mellitus, which significantly impact human health outcomes. The impaired lipid profiles observed in NAFLD individuals can further contribute to cardiovascular events. Despite the high prevalence of NAFLD, there is currently no confirmed intervention approved for its treatment. This study aimed to summarize the results of meta-analysis studies of randomized control trials assessing the impact of gut microbial therapy (probiotics, synbiotics, and prebiotics) on the lipid profile of individuals with NAFLD.

methodsA systematic search was conducted on PubMed, Scopus, Web of Science, and Cochrane Library up to November 1, 2022. Meta-analyses surveying the impact of microbial therapy on lipid profile parameters (triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol (TC)) in the NAFLD population were included in our umbrella review. The final effect size (ES) was estimated, and sensitivity and subgroup analyses were performed to explore heterogeneity.

resultsFifteen studies were included in this umbrella review. Microbial therapy significantly reduced TG (ES - 0.31, 95% CI - 0.51, - 0.11, P < 0.01), TC (ES - 1.04, 95% CI - 1.46, - 0.61, P < 0.01), and LDL (ES - 0.77, 95% CI - 1.15, - 0.39, P < 0.01) in individuals with NAFLD. However, the effect on HDL was not statistically significant (ES - 0.06; 95% CI - 0.19, 0.07, P = 0.39).

conclusionConsidering the absence of approved treatments for NAFLD and the promising role of microbial therapies in improving the three lipid profiles components in individuals with NAFLD, the use of these agents as alternative treatment options could be recommended. The findings underscore the potential of gut microbial therapy, including probiotics, synbiotics, and prebiotics, in managing NAFLD and its associated metabolic complications.

trial registrationPROSPERO ( CRD42022346998 ).

Indexed as

Gastrointestinal MicrobiomeNon-alcoholic Fatty Liver DiseaseProbioticsHumansLipoproteins, HDLMeta-Analysis as TopicPrebioticsRandomized Controlled Trials as TopicLipoproteins, HDLPrebioticsLipid profileMicrobial therapyNon-alcoholic fatty liver diseaseProbioticsSystematic reviewUmbrella meta-analysis

Identifiers

PMID37605283
PMCPMC10441764
OpenAlexW4386033594

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.